FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283383820> ?p ?o ?g. }

• W4283383820 abstract "Excessive proinflammatory cytokine production induced by abnormal activation of Toll-like receptor (TLR) signaling, for example, by SARS-CoV-2 infection, can cause a fatal cytokine storm. The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine, used to treat depression, were recently reported to reduce the risk of severe disease in patients with coronavirus disease 2019 (COVID-19), but the mechanisms of the anti-inflammatory effects of SSRIs, and which SSRI would be most suitable as an anti-inflammatory drug, remain unclear. Here, we examined the inhibitory effects of 5 FDA-approved SSRIs, paroxetine, fluoxetine, fluvoxamine, sertraline and escitalopram, on the production of interleukin-6 (IL-6) induced by stimulation with multiple TLR agonists in murine macrophages and dendritic cells, and on the production of cytokines induced by concanavalin A in murine lymphocytes. In J774.1 murine macrophage cells, pretreatment with SSRIs significantly suppressed IL-6 release induced by TLR3 agonist poly(I:C), TLR4 agonist LPS or TLR9 agonist CpG ODN, but did not affect IL-6 release induced by TLR7 agonists imiquimod or resiquimod. In accordance with the results obtained in J774.1 cells, pretreatment with SSRIs also suppressed IL-6 release induced by a TLR3, TLR4 or TLR9 agonist in bone marrow-derived dendritic cells and peritoneal cells of C57BL/6 mice. On the other hand, interestingly, sertraline alone among the SSRIs amplified IL-6 production induced by TLR7 agonists in murine dendritic cells, though not in macrophages. Concanavalin A-induced production of IL-6 or IL-2 in murine lymphocytes was suppressed by SSRIs, suggesting that SSRIs also inhibit TLRs-independent IL-6 production. Since SSRIs suppressed both IL-6 production induced by multiple TLR agonists in macrophages or dendritic cells and TLR-independent IL-6 production in lymphocytes, they are promising candidates for treatment of patients with cytokine storm, which is mediated by overactivation of multiple TLRs in a complex manner, leading to the so-called IL-6 amplifier, an IL-6 overproduction loop. However, the 5 SSRIs examined here all showed different effects. Overall, our results suggest that fluoxetine may be the most promising candidate as an anti-inflammatory drug. An examination of the structural requirements indicated that the N-methyl group of fluoxetine has a critical role in the inhibition of IL-6 production." @default.
• W4283383820 created "2022-06-25" @default.
• W4283383820 creator A5007030131 @default.
• W4283383820 creator A5022465750 @default.
• W4283383820 creator A5035471848 @default.
• W4283383820 creator A5037342550 @default.
• W4283383820 creator A5052444654 @default.
• W4283383820 creator A5066391245 @default.
• W4283383820 date "2022-06-22" @default.
• W4283383820 modified "2023-10-17" @default.
• W4283383820 title "Profiling Differential Effects of 5 Selective Serotonin Reuptake Inhibitors on TLRs-Dependent and -Independent IL-6 Production in Immune Cells Identifies Fluoxetine as Preferred Anti-Inflammatory Drug Candidate" @default.
• W4283383820 cites W1670369534 @default.
• W4283383820 cites W1814157459 @default.
• W4283383820 cites W1964678173 @default.
• W4283383820 cites W1969072247 @default.
• W4283383820 cites W1971957437 @default.
• W4283383820 cites W1976648523 @default.
• W4283383820 cites W1981164474 @default.
• W4283383820 cites W1983736296 @default.
• W4283383820 cites W1987785379 @default.
• W4283383820 cites W1991105193 @default.
• W4283383820 cites W1995687189 @default.
• W4283383820 cites W2013256329 @default.
• W4283383820 cites W2017096331 @default.
• W4283383820 cites W2033410559 @default.
• W4283383820 cites W2034316161 @default.
• W4283383820 cites W2060122053 @default.
• W4283383820 cites W2062017736 @default.
• W4283383820 cites W2066364269 @default.
• W4283383820 cites W2066889739 @default.
• W4283383820 cites W2074152887 @default.
• W4283383820 cites W2090977130 @default.
• W4283383820 cites W2115563225 @default.
• W4283383820 cites W2130218253 @default.
• W4283383820 cites W2130371437 @default.
• W4283383820 cites W2274885009 @default.
• W4283383820 cites W2583844387 @default.
• W4283383820 cites W2595144937 @default.
• W4283383820 cites W2605016096 @default.
• W4283383820 cites W2608743161 @default.
• W4283383820 cites W2617620062 @default.
• W4283383820 cites W2762418691 @default.
• W4283383820 cites W2783775582 @default.
• W4283383820 cites W2884427097 @default.
• W4283383820 cites W2912679257 @default.
• W4283383820 cites W2914443670 @default.
• W4283383820 cites W2915001911 @default.
• W4283383820 cites W2916627882 @default.
• W4283383820 cites W2918478044 @default.
• W4283383820 cites W2973812625 @default.
• W4283383820 cites W2998853022 @default.
• W4283383820 cites W3005020329 @default.
• W4283383820 cites W3005520297 @default.
• W4283383820 cites W3092207907 @default.
• W4283383820 cites W3102920585 @default.
• W4283383820 cites W3108020863 @default.
• W4283383820 cites W3120281312 @default.
• W4283383820 cites W3130126061 @default.
• W4283383820 cites W3131776523 @default.
• W4283383820 cites W3208556307 @default.
• W4283383820 cites W3217600890 @default.
• W4283383820 cites W4234490266 @default.
• W4283383820 doi "https://doi.org/10.3389/fphar.2022.874375" @default.
• W4283383820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35814203" @default.
• W4283383820 hasPublicationYear "2022" @default.
• W4283383820 type Work @default.
• W4283383820 citedByCount "1" @default.
• W4283383820 countsByYear W42833838202022 @default.
• W4283383820 crossrefType "journal-article" @default.
• W4283383820 hasAuthorship W4283383820A5007030131 @default.
• W4283383820 hasAuthorship W4283383820A5022465750 @default.
• W4283383820 hasAuthorship W4283383820A5035471848 @default.
• W4283383820 hasAuthorship W4283383820A5037342550 @default.
• W4283383820 hasAuthorship W4283383820A5052444654 @default.
• W4283383820 hasAuthorship W4283383820A5066391245 @default.
• W4283383820 hasBestOaLocation W42833838201 @default.
• W4283383820 hasConcept C126322002 @default.
• W4283383820 hasConcept C134018914 @default.
• W4283383820 hasConcept C170493617 @default.
• W4283383820 hasConcept C185592680 @default.
• W4283383820 hasConcept C203014093 @default.
• W4283383820 hasConcept C2777669559 @default.
• W4283383820 hasConcept C2778690821 @default.
• W4283383820 hasConcept C2778938600 @default.
• W4283383820 hasConcept C2779177272 @default.
• W4283383820 hasConcept C2781161787 @default.
• W4283383820 hasConcept C71924100 @default.
• W4283383820 hasConcept C98274493 @default.
• W4283383820 hasConceptScore W4283383820C126322002 @default.
• W4283383820 hasConceptScore W4283383820C134018914 @default.
• W4283383820 hasConceptScore W4283383820C170493617 @default.
• W4283383820 hasConceptScore W4283383820C185592680 @default.
• W4283383820 hasConceptScore W4283383820C203014093 @default.
• W4283383820 hasConceptScore W4283383820C2777669559 @default.
• W4283383820 hasConceptScore W4283383820C2778690821 @default.
• W4283383820 hasConceptScore W4283383820C2778938600 @default.
• W4283383820 hasConceptScore W4283383820C2779177272 @default.
• W4283383820 hasConceptScore W4283383820C2781161787 @default.
• W4283383820 hasConceptScore W4283383820C71924100 @default.
• W4283383820 hasConceptScore W4283383820C98274493 @default.

• next